Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BioAtla, Inc. logo — Safer, more effective drugs for cancer using a proprietary n...

BioAtla, Inc.

Safer, more effective drugs for cancer using a proprietary next generation antibody discovery and evolution platform

Founded 2007 United States San Diego, United States 35 employees IPO Total: $493.00M Biotechnology, Health Care

General Information

Company Name BioAtla, Inc.
Founded Year 2007
Location United States San Diego, United States
Founders / Decision Makers
Team member Team member
Employees 35
Industries Biotechnology, Health Care
Funding Stage IPO
Social

Get notified when BioAtla, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About BioAtla, Inc.

BioAtla is a protein therapeutic company utilizing discovery and evolution to develop safer and more potent drugs for cancer treatment. The company's expertise, backed by 150+ patents and patent applications, culminates in its Conditionally Active Biologics (CAB) platform, enabling the engineering of monoclonal antibodies and biologics for selective conditional activation. This innovation, such as preferential binding under the unique conditions of the tumor microenvironment, enhances tumor selectivity, addressing on-target toxicity and improving the therapeutic index. Founded in 2007 and headquartered in the United States, BioAtla is focused on applying these technologies in its pipeline and partnerships to deliver improved immunotherapies for cancer. The last investment round amounted to $65.00M in Post-IPO Equity and was made on 04 November 2022, with participation from prominent investors like Vivo Capital, Acuta Capital, Adage Capital Management, Cormorant Asset Management, EcoR1 Capital, Janus Handerson, and Soleus Capital.

Taxonomy: Protein Therapeutics, Cancer Treatment, Discovery, Evolution, Monoclonal Antibodies, Biologics, Conditional Activation, Tumor Microenvironment, On-Target Toxicity, Therapeutic Index, Immunotherapies, BioAtla, Biomedical Technology, Clinical Research, Patents

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Debt •••••• 1
Investor
01 Nov 2025
Post Ipo Equity •••••• 5
Investor Investor Investor Investor Investor
01 Nov 2022
Post Ipo Equity •••••• 6
Investor Investor Investor Investor Investor Investor
01 Sep 2021
IPO •••••• - 01 Dec 2020
Series D •••••• 8
Investor Investor Investor Investor Investor Investor Investor Investor
01 Jul 2020

View All 7 Funding Rounds

BioAtla, Inc. Alternatives & Competitors

BioAtla, Inc. vs
Imuno Therapeutics
Imuno Therapeutics The Netherlands

Identifying true targets in oncology and autoimmune disorders

Seed
11 employees
Health Care, Health and Wellness
Compare BioAtla, Inc. vs Imuno Therapeutics
BioAtla, Inc. vs
OncoNano Medicine, Inc.
OncoNano Medicine, Inc. United States

OncoNano is harnessing the power of nanotechnology to unlock a new era of targeted therapeutics. Our...

Series B
23 employees
Biotechnology, Health Care
Compare BioAtla, Inc. vs OncoNano Medicine, Inc.
BioAtla, Inc. vs
Precision Biologics, Inc.
Precision Biologics, Inc. United States

Precision Biologics, Inc. has a cancer immunotherapy platform with 2 unique clinical stage monoclona...

Series Unknown
12 employees
Biotechnology, Health Care
Compare BioAtla, Inc. vs Precision Biologics, Inc.

FAQ About BioAtla, Inc.

Safer, more effective drugs for cancer using a proprietary next generation antibody discovery and evolution platform
BioAtla, Inc. was founded in 2007.
BioAtla, Inc. is headquartered in San Diego, United States.
BioAtla, Inc. operates in the following industries: Biotechnology, Health Care.
BioAtla, Inc. has approximately 35 employees.
BioAtla, Inc. has completed 7 funding rounds, raising a total of $493.00M. The latest funding stage is IPO.
Top alternatives and competitors to BioAtla, Inc. include Imuno Therapeutics, OncoNano Medicine, Inc., Precision Biologics, Inc. , SystImmune, BioLogics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioAtla, Inc. and Imuno Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors BioAtla, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy